Evidence map›Paper›PMID 35454823›Full record

ArticleCancers2022

Outcome after Radiotherapy for Vestibular Schwannomas (VS)-Differences in Tumor Control, Symptoms and Quality of Life after Radiotherapy with Photon versus Proton Therapy.

Maike Küchler, Rami A El Shafie, Sebastian Adeberg, Klaus Herfarth, Laila König, Kristin Lang, Juliane Hörner-Rieber, Peter Karl Plinkert, Wolfgang Wick, Felix Sahm and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Evidence-based indications for proton therapy in adults determined using the GRADE approach.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Maike KüchlerDepartment of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany.
Rami A El ShafieDepartment of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany.
Sebastian AdebergDepartment of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany.ORCID 0000-0001-8463-514X
Klaus HerfarthDepartment of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany.
Laila KönigDepartment of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany.
Kristin LangDepartment of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany.
Juliane Hörner-RieberHeidelberg Institute of Radiation Oncology (HIRO), INF 400, 69120 Heidelberg, Germany.
Peter Karl PlinkertDepartment of Otolaryngology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany.
Wolfgang WickDepartment of Neurology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany.
Felix SahmDeutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Heidelberg, INF 280, 69120 Heidelberg, Germany.
Simon David SprengelDepartment of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany.
Jürgen DebusDepartment of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany.
Denise BernhardtDepartment of Radiation Oncology, University Hospital of Heidelberg, INF 400, 69120 Heidelberg, Germany.
Heidelberg University · DEGerman Cancer Research Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo evaluate differences in local tumor control (LC), symptoms and quality of life (QOL) of 261 patients with VS after stereotactic radiosurgery/hypofractionated stereotactic radiotherapy (SRS/HFSRT) vs. fractionated radiotherapy (FRT) vs. fractionated proton therapy (FPT) were studied.

methodsFor SRS/HFSRT (

resultsLC was 99.5% at 12 months after RT with no statistical difference between treatment groups (

conclusionSRS/HFSRT, FRT and FPT for VS show similar overall clinical and functional outcomes. Cranial nerve impairment rates vary, potentially due to selection bias with larger VS in the FRT and FPT group.

Indexed as

clinical outcomehearing preservationproton therapyquality of lifestereotactic radiotherapytumor controlvestibular schwannomas

Identifiers

PMID35454823
PMCPMC9025388
OpenAlexW4223461741

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.